LITAF regulation of cell death and inflammatory responses

LITAF 调节细胞死亡和炎症反应

基本信息

项目摘要

Project Summary Membrane damage by mechanical or biochemical stress, leads to cell death and activation of innate immune inflammatory pathways, and contributes to the pathology of many inflammatory conditions. Furthermore, pathogens can secrete pore-forming toxins (PFT) to promote infection and disrupt immunity, and endogenous pore-forming proteins such as Gasdermin D and MLKL have been shown to contribute to inflammatory signaling and secretion of cytokines. Cells have evolved multiple mechanisms to repair membrane damage and maintain cellular homeostasis, but our understanding of how damage is sensed and linked to repair remains incomplete. We have recently developed a transposon-based forward genetic screening approach, which we have used to identify genes that promote resistance to cell death induced by S. aureus α-toxin. We identified the lysosomal membrane protein LITAF as a cell-autonomous inhibitor of cell death. In preliminary data, we show that LITAF promotes sequestration of damaged membranes into vesicles through the activation of the ESCRT machinery. We hypothesize that LITAF acts as an effector of cellular defense against pore-forming proteins, linking sensing of membrane damage to effector mechanisms of repair. In this application, we propose to test this hypothesis by: (1) identifying the mechanisms of LITAF activation and function; (2) determining the role of this pathway in lung inflammation and infection; (3) testing whether LITAF regulates innate immune signaling, inflammasome activation and inflammatory cell death in macrophages. This research is of high significance as it will provide a deeper understanding of cellular defense mechanisms against membrane damage, and of the balance between cell survival and inflammatory cell death. Identifying strategies to counteract membrane damage and prevent cell death will contribute to understanding and treating the pathology of a wide range of infectious and inflammatory diseases.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Adam Lacy-Hulbert其他文献

Adam Lacy-Hulbert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Adam Lacy-Hulbert', 18)}}的其他基金

Immune Signatures and Clinical Outcomes in Acute Pancreatitis
急性胰腺炎的免疫特征和临床结果
  • 批准号:
    10568011
  • 财政年份:
    2023
  • 资助金额:
    $ 29.96万
  • 项目类别:
alpha v integrin regulation of B cell tolerance
B 细胞耐受的 α v 整合素调节
  • 批准号:
    10294130
  • 财政年份:
    2020
  • 资助金额:
    $ 29.96万
  • 项目类别:
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis
使用转座子诱变鉴定流感宿主药物开发靶点
  • 批准号:
    8956296
  • 财政年份:
    2015
  • 资助金额:
    $ 29.96万
  • 项目类别:
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis
使用转座子诱变鉴定流感宿主药物开发靶点
  • 批准号:
    9089858
  • 财政年份:
    2015
  • 资助金额:
    $ 29.96万
  • 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
  • 批准号:
    8883359
  • 财政年份:
    2014
  • 资助金额:
    $ 29.96万
  • 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
  • 批准号:
    8490300
  • 财政年份:
    2012
  • 资助金额:
    $ 29.96万
  • 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
  • 批准号:
    8868105
  • 财政年份:
    2012
  • 资助金额:
    $ 29.96万
  • 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
  • 批准号:
    8372489
  • 财政年份:
    2012
  • 资助金额:
    $ 29.96万
  • 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
  • 批准号:
    8391403
  • 财政年份:
    2012
  • 资助金额:
    $ 29.96万
  • 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
  • 批准号:
    8843114
  • 财政年份:
    2012
  • 资助金额:
    $ 29.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了